TEMPO.CO, Jakarta - The Indonesian Health Minister Budi Gunawan Sadikin announced in a press conference on Wednesday, December 30, 2020, that state-pharmaceutical firm BioFarma has signed a deal to purchase Covid-19 vaccines from UK-based AstraZeneca, and Novavax in the United States.
From the two companies, BioFarma reportedly ordered 100 million doses of vaccines in total.
"This will provide sufficient variations for the Indonesian population in regards to the vaccine products used," said Health Minister Budi Gunadi Sadikin.
AstraZeneca and Novavax are two out of five options the Indonesian government has prepared for the future nationwide vaccination program. Other vaccine sources are China-based Sinovac, US-based Pfizer, and the COVAVAX/GAVI that comes from a multilateral partnership.
With additions to the 100 million doses from AstraZeneca and Novavax, Indonesia has placed firm orders for 329 million doses in total with 125 million doses coming from Sinovac, 50 million doses from Pfizer, and 54 million doses from COVAVAX/GAVI.
The government has concluded that it will need 426 million doses in total for the country's 181 million population.